Clinical Scorecard: Selective JAK Inhibition in RA vs PV
At a Glance
| Category | Detail |
|---|---|
| Condition | Rheumatoid Arthritis with Polycythemia Vera |
| Key Mechanisms | Selective inhibition of JAK1 and JAK3, sparing JAK2 activity. |
| Target Population | Patients with seropositive rheumatoid arthritis and JAK2 V617F-positive polycythemia vera. |
| Care Setting | Rheumatology and hematology clinics. |
Key Highlights
- Tofacitinib demonstrated efficacy in RA but minimal effect on PV-related hematologic activity.
- Patient achieved clinical and ultrasonographic remission of RA within 3 months of tofacitinib initiation.
- Hematologic parameters remained stable during follow-up.
- Limited impact on erythrocytosis highlights need for JAK2-directed therapies.
- No adverse events or cytopenias reported after 12 months.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of RA based on chronic symmetric polyarthritis and positive autoantibodies.
- Bone marrow biopsy to confirm PV.
Management
- Initiate treatment with tofacitinib for RA in patients with concomitant PV.
- Continue hydroxyurea for PV management.
Monitoring & Follow-up
- Regular assessment of inflammatory markers and joint symptoms.
- Monitor hematologic parameters to avoid complications.
Risks
- Potential for recurrence of erythrocytosis with hydroxyurea tapering.
Patient & Prescribing Data
61-year-old woman with seropositive RA and JAK2 V617F-positive PV.
Tofacitinib effectively induced RA remission while maintaining hematologic safety.
Clinical Best Practices
- Consider JAK2-directed therapies for patients with overlapping autoimmune and myeloproliferative diseases.
- Monitor for gastrointestinal intolerance and skin reactions when prescribing DMARDs.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
